Insider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells 1,750 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,750 shares of the firm’s stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $25.74, for a total value of $45,045.00. Following the sale, the insider now directly owns 1,737 shares of the company’s stock, valued at $44,710.38. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Monday, April 1st, Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.78, for a total value of $259,102.34.
• On Wednesday, March 27th, Scott Bizily sold 5,833 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $35.04, for a total value of $204,388.32.
• On Monday, March 18th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $31.27, for a total value of $54,722.50.
• On Tuesday, February 27th, Scott Bizily sold 1,909 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $57,270.00.
• On Friday, February 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.67, for a total value of $48,422.50.
• On Thursday, February 8th, Scott Bizily sold 6,244 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $27.50, for a total value of $171,710.00.

4D Molecular Therapeutics Trading Down 2.1 %

FDMT stock opened at $24.78 on Friday. 4D Molecular Therapeutics, Inc. has a 1-year low of $9.44 and a 1-year high of $36.25. The business’s 50-day moving average price is $28.97 and its two-hundred day moving average price is $20.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, February 29th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.09). 4D Molecular Therapeutics had a negative net margin of 436.30% and a negative return on equity of 34.14%. The business had revenue of ($0.02) million during the quarter, compared to analyst estimates of $4.67 million. As a group, analysts expect that 4D Molecular Therapeutics, Inc. will post -3.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Barclays assumed coverage on 4D Molecular Therapeutics in a research report on Monday. They issued an “overweight” rating on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $81.00 price objective on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 7th. Jefferies Financial Group increased their price objective on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Royal Bank of Canada raised their price target on 4D Molecular Therapeutics from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, March 1st. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $44.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC grew its stake in 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after acquiring an additional 3,026 shares during the period. Wellington Management Group LLP grew its stake in 4D Molecular Therapeutics by 4.5% in the fourth quarter. Wellington Management Group LLP now owns 180,475 shares of the company’s stock valued at $3,656,000 after acquiring an additional 7,753 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 415.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 816,343 shares of the company’s stock valued at $16,539,000 after purchasing an additional 658,069 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of 4D Molecular Therapeutics by 5.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,596 shares of the company’s stock valued at $458,000 after purchasing an additional 1,106 shares in the last quarter. Finally, Virtus ETF Advisers LLC lifted its holdings in shares of 4D Molecular Therapeutics by 24.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,574 shares of the company’s stock valued at $113,000 after purchasing an additional 1,095 shares in the last quarter. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.